Dr. Hsieh, Patrick Ching-Ho 's publons link picture

Dr. Hsieh, Patrick Ching-Ho

Distinguished Research Fellow
Division Chief
  • 02-27899170 (Lab) (Room No: N417)
  • 02-27858594 (Fax)

Specialty:
  • Stem cells and regenerative medicine
  • Nanoscience and nanomedicine
  • Translational Research

Education and Positions:
  • M.D. Kaohsiung Medical College
    Ph.D. University of Washington, Seattle (Bioengineering)


  • Personal CV

  • Highlight Detail
    ...

    Primary cardiac manifestation of autosomal dominant polycystic kidney disease revealed by patient induced pluripotent stem cell-derived cardiomyocytes

    Dr. Hsieh, Patrick Ching-Ho
    EBioMedicine, Jan 11, 2019

    BACKGROUND:

    Mutations in PKD1 or PKD2 gene lead to autosomal dominant polycystic kidney disease (ADPKD). The mechanism of ADPKD progression and its link to increased cardiovascular mortality is still elusive.

    METHODS:

    We differentiated ADPKD patient induced pluripotent stem cells (iPSCs) to cardiomyocytes (CMs). The electrophysiological properties at the cellular level were analyzed by calcium imaging and whole cell patch clamping.

    FINDINGS:

    The ADPKD patient iPSC-CMs had decreased sarcoplasmic reticulum calcium content compared with Control-CMs. Spontaneous action potential of the PKD2 mutation line-derived CMs demonstrated slower beating rate and longer action potential duration. The PKD1 mutation line-derived CMs showed a comparable dose-dependent shortening of phase II repolarization with the Control-CMs, but a significant increase in beating frequency in response to L-type calcium channel blocker. The PKD1-mutant iPSC-CMs also showed a relatively unstable baseline as a greater percentage of cells exhibited delayed afterdepolarizations (DADs). Both the ADPKD patient iPSC-CMs showed more β-adrenergic agonist-elicited DADs compared with Control-CMs.

    INTERPRETATION:

    Characterization of ADPKD patient iPSC-CMs provides new insights into the increased clinical risk of arrhythmias, and the results enable disease modeling and drug screening for cardiac manifestations of ADPKD. FUND: Ministry of Science and Technology, National Health Research Institutes, Academia Sinica Program for Technology Supporting Platform Axis Scheme, Thematic Research Program and Summit Research Program, and Kaohsiung Medical University Hospital, Taiwan.